Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses
- 13 August 2014
- journal article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 12 (10) , 1171-1178
- https://doi.org/10.1586/14787210.2014.948847
Abstract
CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.Keywords
This publication has 42 references indexed in Scilit:
- Emergence of Cowpox: Study of the Virulence of Clinical Strains and Evaluation of AntiviralsPLOS ONE, 2013
- Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpoxAntiviral Research, 2012
- The eradication of smallpox – An overview of the past, present, and futurePublished by Elsevier ,2011
- FDA Experience with Medical Countermeasures under the Animal RuleAdvances in Preventive Medicine, 2011
- Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of HumansViruses, 2011
- Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246Viruses, 2010
- Ectromelia Virus Infections of Mice as a Model to Support the Licensure of Anti-Orthopoxvirus TherapeuticsViruses, 2010
- Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of CidofovirAntimicrobial Agents and Chemotherapy, 2004
- Smallpox Research Activities: U.S. Interagency Collaboration, 2001Emerging Infectious Diseases, 2002
- Diagnosis and Management of SmallpoxNew England Journal of Medicine, 2002